Zanubrutinib is currently evaluated across numerous clinical trials spanning Phase 1 through Phase 4, with statuses ranging from actively recruiting to completed. Research focuses on various B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma, as well as non-malignant conditions such as immune thrombocytopenia. Supported by pharmaceutical sponsors like BeiGene alongside academic research centers, these studies encompass Phase 2 monotherapy investigations and late-stage comparative evaluations in relapsed or refractory hematologic populations.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05976763 | RECRUITING | Mantle Cell Lymphoma |
Alliance for Clinical Trials in Oncology |
2023-10-20 | PHASE3 |
| NCT07474961 | NOT_YET_RECRUITING | Waldenstrom Macroglobulinaemia; Multiple Myeloma |
Anne Louise Tølbøll Sørensen |
2027-03 | PHASE4 |
| NCT07638722 | NOT_YET_RECRUITING | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma |
SWOG Cancer Research Network |
2026-10-03 | PHASE2 |
| NCT06544785 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
PETHEMA Foundation |
2024-09-02 | PHASE2 |
| NCT06073821 | ACTIVE_NOT_RECRUITING | CLL |
BeOne Medicines |
2023-11-11 | PHASE3 |
| NCT06824701 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
University of Utah |
2025-09-12 | PHASE1 |
| NCT07377578 | RECRUITING | Mantle Cell Lymphoma |
Guangzhou Lupeng Pharmaceutical Company LTD. |
2026-02-05 | PHASE3 |
| NCT07299331 | NOT_YET_RECRUITING | Marginal Zone Lymphoma(MZL) |
Zhengzhou University |
2026-01-01 | |
| NCT07392229 | RECRUITING | Anti-MAG IgM-associated Demyelinating Polyneuropathy |
Azienda Ospedaliera di Padova |
2026-03-24 | PHASE2 |
| NCT07277231 | RECRUITING | Chronic Lymphocytic Leukemia |
BeOne Medicines |
2026-01-22 | PHASE3 |
| NCT06503263 | RECRUITING | Diffuse Large B-cell Lymphoma |
Navy General Hospital, Beijing |
2024-08-30 | PHASE2 |
| NCT06520098 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
VA Office of Research and Development |
2025-10-01 | PHASE2 |
| NCT06730542 | RECRUITING | CNS Lymphoma |
Juan P. Alderuccio, MD |
2025-04-17 | PHASE1 |
| NCT07505849 | NOT_YET_RECRUITING | Follicular Lymphomas |
KeshuZhou |
2026-03-23 | PHASE2 |
| NCT06367374 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2024-05-30 | PHASE2 |
| NCT07682415 | NOT_YET_RECRUITING | CLL / SLL |
Yi Shuhua |
2026-06-08 | PHASE2 |
| NCT06890585 | NOT_YET_RECRUITING | BTK Inhibitors; Histone Deacetylase Inhibitor; Double Express Diffuse Large B-cell Lymphoma |
Li Zhiming |
2025-06-01 | PHASE2 |
| NCT07341191 | RECRUITING | Mantle Cell Lymphoma |
Canadian Cancer Trials Group |
2026-08-24 | PHASE2 |
| NCT06664411 | RECRUITING | Diffuse Large B-cell Lymphoma |
Navy General Hospital, Beijing |
2024-09-24 | PHASE2 |
| NCT06697184 | RECRUITING | Chronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma; MCL |
BeOne Medicines |
2025-01-23 | PHASE1; PHASE2 |
| NCT06854003 | RECRUITING | Mantle Cell Lymphoma; Lymphoma |
Christine Ryan |
2025-04-22 | PHASE2 |
| NCT06846463 | RECRUITING | Diffuse Large B-cell Lymphoma; DLBCL - Diffuse Large B Cell Lymphoma |
Virginia Commonwealth University |
2025-05-27 | PHASE2 |
| NCT07717177 | NOT_YET_RECRUITING | Large B-Cell Lymphoma (LBCL) |
Ruijin Hospital |
2026-06-30 | PHASE2 |
| NCT07594899 | NOT_YET_RECRUITING | Large B-Cell Lymphoma (LBCL) |
Ruijin Hospital |
2026-05-06 | PHASE2 |
| NCT05735834 | ACTIVE_NOT_RECRUITING | Splenic Marginal Zone Lymphoma |
International Extranodal Lymphoma Study Group (IELSG) |
2024-05-21 | PHASE3 |
| NCT06812715 | RECRUITING | Chronic Lymphocytic Leukemia |
Peter MacCallum Cancer Centre, Australia |
2025-05-05 | PHASE2 |
| NCT06167785 | RECRUITING | Large B-cell Lymphoma |
University Health Network, Toronto |
2025-06-04 | PHASE2 |
| NCT07739459 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
The Lymphoma Academic Research Organisation |
2026-12 | PHASE2 |
| NCT07548255 | NOT_YET_RECRUITING | Intermediate-to-High-Risk Mantle Cell Lymphoma; the Efficacy and Safety |
Ruijin Hospital |
2026-04-20 | PHASE1 |
| NCT06350318 | RECRUITING | Follicular Lymphoma; Marginal Zone Lymphoma; B-Cell Lymphoma |
H. Lee Moffitt Cancer Center and Research Institute |
2024-04-19 | PHASE2 |
| NCT06859008 | RECRUITING | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma |
City of Hope Medical Center |
2025-08-25 | PHASE1 |
| NCT06665217 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma |
Navy General Hospital, Beijing |
2025-09-24 | PHASE2 |
| NCT07690761 | ENROLLING_BY_INVITATION | Hairy Cell Leukemia; Hairy Cell Leukemia Variant |
Bnai Zion Medical Center |
2026-06-01 | PHASE2 |
| NCT07514169 | RECRUITING | Large B-Cell Lymphoma (LBCL) |
Ruijin Hospital |
2026-03-31 | PHASE2 |
| NCT07052695 | RECRUITING | Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma |
Inhye Ahn |
2025-11-24 | PHASE1; PHASE2 |
| NCT07608978 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
The First Affiliated Hospital with Nanjing Medical University |
2026-06-01 | PHASE2 |
| NCT07165769 | RECRUITING | Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN |
Institute of Hematology & Blood Diseases Hospital, China |
2025-09-04 | PHASE2 |
| NCT06547866 | NOT_YET_RECRUITING | Waldenstrom Macroglobulinemia |
French Innovative Leukemia Organisation |
2025-12-01 | PHASE2 |
| NCT07315373 | NOT_YET_RECRUITING | Immune Thrombocytopenia |
Peking University People's Hospital |
2025-12-25 | PHASE1 |
| NCT06634589 | RECRUITING | B-cell Malignancy; Relapsed Cancer; Refractory Cancer; B-cell Lymphoma |
BeOne Medicines |
2024-11-27 | PHASE1; PHASE2 |
| NCT06463691 | RECRUITING | MCL |
Tianjin Medical University Cancer Institute and Hospital |
2024-08-01 | PHASE2 |
| NCT07169331 | ACTIVE_NOT_RECRUITING | Waldenström's Macroglobulinemia |
BeiGene |
2025-10-17 | PHASE4 |
| NCT05635162 | RECRUITING | Mantle Cell Lymphoma |
University College, London |
2024-05-17 | PHASE2 |
| NCT07321652 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia |
Alliance for Clinical Trials in Oncology |
2026-04-30 | PHASE3 |
| NCT06492837 | RECRUITING | Follicular Lymphoma |
Fondazione Italiana Linfomi - ETS |
2024-10-23 | PHASE2 |
| NCT07799220 | NOT_YET_RECRUITING | Mantle Cell Lymphoma |
Memorial Sloan Kettering Cancer Center |
2026-09 | PHASE2 |
| NCT06647732 | RECRUITING | Mucosa-associated Lymphoid Tissue Lymphoma (MALT) |
Sun Yat-sen University |
2024-10-30 | PHASE2 |
| NCT06742996 | RECRUITING | Mantle Cell Lymphoma; B Cell Lymphoma |
BeOne Medicines |
2025-03-05 | PHASE3 |
| NCT06522555 | RECRUITING | Diffuse Large B-Cell Lymphoma |
Ruijin Hospital |
2024-07-29 | PHASE3 |
| NCT06839053 | RECRUITING | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Mantle Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Mantle Cell Lymphoma; Refractory Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma |
Fred Hutchinson Cancer Center |
2025-06-02 | PHASE2 |
| NCT07126678 | RECRUITING | Follicular Lymphoma; Treatment Naive |
The First Affiliated Hospital with Nanjing Medical University |
2025-07-15 | |
| NCT05100862 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma |
BeOne Medicines |
2022-03-10 | PHASE3 |
| NCT07259122 | NOT_YET_RECRUITING | Waldenström Macroglobulinemia (WM) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-12-30 | PHASE2 |
| NCT06029309 | RECRUITING | Mantle Cell Lymphoma |
Alvaro Alencar, MD |
2024-05-03 | PHASE1; PHASE2 |
| NCT06918015 | NOT_YET_RECRUITING | BTK Inhibitors; Follicular Lymphoma; Immunochemotherapy |
Zhejiang Cancer Hospital |
2025-05-01 | PHASE2 |
| NCT06558604 | RECRUITING | Lymphoma, Mantle-Cell |
The Lymphoma Academic Research Organisation |
2025-02-21 | PHASE2 |
| NCT06803693 | RECRUITING | Diffuse Large B-Cell Lymphoma |
Ruijin Hospital |
2025-04-01 | PHASE2 |
| NCT07299149 | RECRUITING | Follicular Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-12-25 | PHASE2 |
| NCT04840602 | RECRUITING | Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia |
National Cancer Institute (NCI) |
2022-01-05 | PHASE2 |
| NCT07550855 | NOT_YET_RECRUITING | Follicular Lymphoma (FL) |
Sun Yat-sen University |
2026-09-01 | PHASE2 |
| NCT06849713 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL) |
Massachusetts General Hospital |
2025-05-16 | PHASE2 |
| NCT06563596 | RECRUITING | Follicular Lymphoma; Lymphoma; Non-Hodgkin Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Marginal Zone Lymphoma |
Reid Merryman, MD |
2025-01-21 | PHASE2 |
| NCT07371923 | RECRUITING | Diffuse Large B Cell Lymphoma (DLBCL) |
Beijing Tongren Hospital |
2025-11-20 | PHASE2 |
| NCT05681195 | RECRUITING | Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Relapsed Cancer; Refractory Cancer |
Baptist Health South Florida |
2024-04-25 | PHASE2 |
| NCT06646211 | NOT_YET_RECRUITING | Primary Central Nervous System Lymphoma (PCNSL); Non Hodgkin Lymphoma (NHL) |
Sun Yat-sen University |
2025-01-01 | PHASE2 |
| NCT07418190 | RECRUITING | Relapsed/Refractory Follicular Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2026-02-01 | PHASE2 |
| NCT07671378 | RECRUITING | CLL (Chronic Lymphocytic Leukemia) |
The First Affiliated Hospital with Nanjing Medical University |
2026-06-01 | PHASE2 |
| NCT07734038 | RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Kerry Rogers |
2026-10-01 | PHASE2 |
| NCT06427213 | NOT_YET_RECRUITING | Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Henan Cancer Hospital |
2024-05-20 | PHASE2 |
| NCT07405255 | NOT_YET_RECRUITING | Central Nervous System Lymphoma |
Ruijin Hospital |
2026-01-30 | PHASE2 |
| NCT06735664 | RECRUITING | Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma |
City of Hope Medical Center |
2025-08-14 | PHASE1 |
| NCT06958705 | RECRUITING | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) |
The First Affiliated Hospital with Nanjing Medical University |
2025-12-01 | PHASE2 |
| NCT05389293 | RECRUITING | Follicular Lymphoma; Lymphoma |
Memorial Sloan Kettering Cancer Center |
2022-05-27 | PHASE2 |
| NCT06474481 | NOT_YET_RECRUITING | FL |
Tianjin Medical University Cancer Institute and Hospital |
2024-07 | PHASE2 |
| NCT06136351 | RECRUITING | Lymphoma, Mantle-Cell |
Ruijin Hospital |
2023-11-15 | PHASE2 |
| NCT07271667 | RECRUITING | Chronic Lymphocytic Leukemia; B-cell Malignancies |
Curis, Inc. |
2026-04-23 | PHASE2 |
| NCT06973811 | RECRUITING | Primary Intraocular Lymphoma |
Peking Union Medical College Hospital |
2024-10-10 | PHASE2 |
| NCT05707377 | ACTIVE_NOT_RECRUITING | Primary Membranous Nephropathy |
BeOne Medicines |
2023-04-17 | PHASE2; PHASE3 |
| NCT04271956 | RECRUITING | Richter Transformation |
German CLL Study Group |
2020-02-19 | PHASE2 |
| NCT07261163 | RECRUITING | Mantle Cell Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-12-20 | PHASE2 |
| NCT06959732 | RECRUITING | Follicular Lymphoma ( FL) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-01-01 | PHASE2 |
| NCT07003464 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia |
The First Hospital of Jilin University |
2025-06-15 | PHASE2 |
| NCT06646666 | NOT_YET_RECRUITING | B-cell Non Hodgkin Lymphoma |
Ruijin Hospital |
2024-12-01 | PHASE2 |
| NCT04277637 | ACTIVE_NOT_RECRUITING | Mature B-Cell Malignancies |
BeOne Medicines |
2020-03-24 | PHASE1 |
| NCT04458610 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2020-05-26 | PHASE2 |
| NCT07674810 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia |
M.D. Anderson Cancer Center |
2026-12-31 | PHASE2 |
| NCT06942507 | NOT_YET_RECRUITING | Waldenström's Macroglobulinemia (WM) |
Peking Union Medical College Hospital |
2025-05-01 | |
| NCT07270835 | RECRUITING | Hemophagocytic Lymphohistiocytosis; B Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2025-11-01 | PHASE4 |
| NCT05650723 | ACTIVE_NOT_RECRUITING | Leukemia, Lymphocytic, Chronic, B-Cell |
Weill Medical College of Cornell University |
2023-05-08 | PHASE2 |
| NCT04002297 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
BeOne Medicines |
2019-08-20 | PHASE3 |
| NCT03824483 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Leukemia (SLL) |
Memorial Sloan Kettering Cancer Center |
2019-02-22 | PHASE2 |
| NCT04515238 | ACTIVE_NOT_RECRUITING | Chronic Lymphoid Leukemia |
German CLL Study Group |
2020-10-01 | PHASE2 |
| NCT04662255 | ACTIVE_NOT_RECRUITING | Lymphoma, Mantle-Cell |
Loxo Oncology, Inc. |
2021-04-08 | PHASE3 |
| NCT06764017 | RECRUITING | Diffuse Large B-Cell Lymphoma |
First Affiliated Hospital of Ningbo University |
2025-02-01 | PHASE2 |
| NCT05890352 | RECRUITING | Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Non-Hodgkin Lymphoma |
SWOG Cancer Research Network |
2023-09-26 | PHASE2 |
| NCT06375733 | RECRUITING | Large B-cell Lymphoma |
Genfleet Therapeutics (Shanghai) Inc. |
2024-03-20 | PHASE1; PHASE2 |
| NCT05939037 | ACTIVE_NOT_RECRUITING | Monoclonal Gammopathy of Uncertain Significance |
UMC Utrecht |
2024-03-01 | PHASE2 |
| NCT04170283 | ACTIVE_NOT_RECRUITING | B-cell Malignancies |
BeOne Medicines |
2020-01-16 | PHASE3 |
| NCT06563505 | RECRUITING | Lymphoma |
M.D. Anderson Cancer Center |
2024-12-11 | PHASE2 |
| NCT06504199 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2024-07-18 | PHASE2 |
| NCT05873712 | RECRUITING | Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed |
Aseel Alsouqi |
2023-07-28 | PHASE2 |
| NCT06471738 | RECRUITING | Ann Arbor Stage II Follicular Lymphoma; Grade 1 Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma |
Chinese PLA General Hospital |
2024-07-10 | PHASE2 |
| NCT06561347 | RECRUITING | Waldenstrom Macroglobulinemia |
Massachusetts General Hospital |
2024-12-20 | PHASE2 |
| NCT06549335 | NOT_YET_RECRUITING | Follicular Lymphoma |
Ruijin Hospital |
2024-12-01 | PHASE2 |
| NCT06594432 | NOT_YET_RECRUITING | Diffuse Large B Cell Lymphoma (DLBCL) |
The First Affiliated Hospital with Nanjing Medical University |
2024-10 | PHASE2 |
| NCT06695013 | RECRUITING | B-NHL; CART Therapy |
Ruijin Hospital |
2024-11-20 | PHASE2 |
| NCT06652165 | NOT_YET_RECRUITING | DLBCL |
Ruijin Hospital |
2024-11-01 | PHASE2 |
| NCT06669143 | NOT_YET_RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2024-11 | PHASE2 |
| NCT06637501 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
BeOne Medicines |
2024-11-14 | PHASE2 |
| NCT05168930 | RECRUITING | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Dana-Farber Cancer Institute |
2022-02-18 | PHASE2 |
| NCT05202782 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma, Not Otherwise Specified; Large B-Cell Lymphoma With IRF4 Rearrangement; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent Intravascular Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Aggressive B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory Intravascular Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma |
Northwestern University |
2022-03-21 | PHASE2 |
| NCT05952037 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory |
BeOne Medicines |
2023-10-23 | PHASE2 |
| NCT05718869 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
City of Hope Medical Center |
2023-05-18 | PHASE2 |
| NCT06554600 | RECRUITING | Refractory or Relapsed Diffuse Large B Cell Lymphoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2024-08-31 | PHASE2 |
| NCT07012980 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma |
Shanghai Zhongshan Hospital |
2025-06-01 | PHASE2 |
| NCT06005870 | RECRUITING | Diffuse Large B Cell Lymphoma |
Huazhong University of Science and Technology |
2022-11-26 | PHASE2 |
| NCT04850495 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma |
Yazeed Sawalha |
2021-11-16 | PHASE1 |
| NCT06468943 | ENROLLING_BY_INVITATION | Effects of Chemotherapy; Safety Issues |
The First Affiliated Hospital of Soochow University |
2023-07-01 | PHASE2 |
| NCT05478512 | ACTIVE_NOT_RECRUITING | High Risk CLL; Chronic Lymphocytic Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2023-07-21 | PHASE2 |
| NCT06553352 | RECRUITING | Follicular Lymphoma; Newly Diagnosed |
The First Affiliated Hospital of Xiamen University |
2024-03-31 | PHASE2 |
| NCT06445257 | UNKNOWN | Primary Central Nervous System Lymphoma |
Huai'an First People's Hospital |
2023-09-15 | |
| NCT06341556 | RECRUITING | Mantle Cell Lymphoma; Maintenance Therapy |
Fudan University |
2024-05-24 | PHASE2 |
| NCT07141511 | COMPLETED | Healthy Volunteers |
BeOne Medicines |
2025-09-24 | PHASE1 |
| NCT06067048 | ACTIVE_NOT_RECRUITING | Lymphoma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-07-26 | PHASE2 |
| NCT04116437 | COMPLETED | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia |
BeiGene |
2019-10-15 | PHASE2 |
| NCT06255704 | NOT_YET_RECRUITING | Mantle Cell Lymphoma |
Shanxi Province Cancer Hospital |
2024-03-15 | PHASE2 |
| NCT05896007 | UNKNOWN | PCNSL |
Ruijin Hospital |
2023-07-13 | PHASE2 |
| NCT05214391 | RECRUITING | Immune Thrombocytopenia; Treatment |
Institute of Hematology & Blood Diseases Hospital, China |
2022-02-15 | PHASE2 |
| NCT05369364 | UNKNOWN | Immune Thrombocytopenia |
Peking University People's Hospital |
2022-06-01 | PHASE2 |
| NCT05179733 | UNKNOWN | Diffuse Large B-Cell Lymphoma |
Ruijin Hospital |
2022-03-02 | PHASE3 |
| NCT06547944 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed |
Institute of Hematology & Blood Diseases Hospital, China |
2024-01-01 | PHASE1 |
| NCT04835870 | UNKNOWN | Non-GCB/ABC Diffuse Large B-Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2021-04-01 | PHASE2 |
| NCT06021977 | UNKNOWN | Refractory/Relapsed Autoimmune Hemolytic Anemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-09-01 | PHASE2 |
| NCT05940064 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Peng Liu |
2023-07-20 | PHASE2 |
| NCT05940051 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Peng Liu |
2023-07-20 | PHASE2 |
| NCT06033820 | UNKNOWN | Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory |
RenJi Hospital |
2023-10-12 | PHASE2 |
| NCT05665530 | COMPLETED | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); Mantle Cell Lymphoma (MCL); Richter's Syndrome; T-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Marginal Zone Lymphoma; Myeloid Malignancies; Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia (CMML); Myelodysplastic Syndrome (MDS); MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome |
Prelude Therapeutics |
2023-09-12 | PHASE1 |
| NCT05348213 | RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2022-05-16 | PHASE2 |
| NCT05369377 | UNKNOWN | Immune Thrombocytopenia |
Peking University People's Hospital |
2022-06-01 | PHASE2 |
| NCT05428670 | UNKNOWN | Diffuse Large B Cell Lymphoma |
First Affiliated Hospital of Wenzhou Medical University |
2022-06-15 | PHASE2 |
| NCT05979948 | UNKNOWN | Waldenström's Macroglobulinemia |
Shanghai Changzheng Hospital |
2023-08-01 | PHASE2 |
| NCT05068440 | COMPLETED | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma |
BeiGene |
2021-08-11 | PHASE2 |
| NCT05914662 | UNKNOWN | Waldenstrom Macroglobulinemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-02-15 | PHASE2 |
| NCT04602598 | COMPLETED | IgG4 Related Disease |
Matthew C. Baker |
2022-08-01 | PHASE2 |
| NCT04743687 | UNKNOWN | Idiopathic Multicentric Castleman's Disease |
Peking Union Medical College Hospital |
2021-01-01 | PHASE2 |
| NCT05189197 | UNKNOWN | Diffuse Large B-cell Lymphoma(DLBCL) |
Fudan University |
2022-01-18 | PHASE2 |
| NCT04624958 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma; Newly-diagnosed Mantle Cell Lymphoma |
Sun Yat-sen University |
2020-12-01 | PHASE2 |
| NCT05922839 | UNKNOWN | Warm Autoimmune Hemolytic Anemia |
Chen Miao |
2023-11-11 | PHASE2 |
| NCT04668365 | SUSPENDED | Diffuse Large B Cell Lymphoma; CD79A Gene Mutation; CD79B Gene Mutation |
Henan Cancer Hospital |
2020-12-25 | PHASE2 |
| NCT05596097 | UNKNOWN | Diffuse Large B-cell Lymphoma (DLBCL) |
LanZhou University |
2022-10-30 | PHASE2 |
| NCT05527912 | UNKNOWN | Double Express Diffuse Large B-cell Lymphoma |
Sun Yat-sen University |
2023-02-24 | PHASE2 |
| NCT04282018 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Advanced Solid Tumor |
BeiGene |
2020-04-29 | PHASE1; PHASE2 |
| NCT05887726 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Liaoning Cancer Hospital & Institute |
2023-08-01 | PHASE2 |
| NCT05797948 | UNKNOWN | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-07-01 | |
| NCT05287984 | UNKNOWN | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed |
Institute of Hematology & Blood Diseases Hospital, China |
2022-03-22 | PHASE2 |
| NCT05290090 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Zhejiang Cancer Hospital |
2021-10-01 | PHASE2 |
| NCT05392257 | UNKNOWN | Overall Survival |
Qingdao Central Hospital |
2022-05-01 | PHASE2 |
| NCT06029309 | Not yet recruiting | Mantle Cell Lymphoma |
Alvaro Alencar MD|BeiGene|Incyte Corporation|MorphoSys AG|University of Miami |
2024-05-01 | Phase 1|Phase 2 |
| NCT04436107 | COMPLETED | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
BeiGene |
2020-09-11 | PHASE1 |
| NCT06350318 | Recruiting | Follicular Lymphoma|Marginal Zone Lymphoma|B-Cell Lymphoma |
H. Lee Moffitt Cancer Center and Research Institute|BeiGene Ltd. |
2024-03-13 | Phase 2 |
| NCT05398224 | UNKNOWN | Secondary Central Nervous System Lymphoma |
Peking University |
2021-02-26 | PHASE2 |
| NCT04643470 | COMPLETED | Lupus Nephritis |
BeiGene |
2020-12-22 | PHASE2 |
| NCT05356858 | TERMINATED | Neuromyelitis Optica |
Xuanwu Hospital, Beijing |
2022-05-07 | PHASE2 |
| NCT05200312 | UNKNOWN | Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2022-02-01 | PHASE2 |
| NCT06067048 | Not yet recruiting | Lymphoma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-02-01 | Phase 2 |
| NCT05290337 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Fudan University |
2022-01-04 | PHASE2 |
| NCT05199909 | RECRUITING | Antiphospholipid Syndrome; Thrombocytopenia; Treatment |
Institute of Hematology & Blood Diseases Hospital, China |
2022-01-25 | PHASE2 |
| NCT05164770 | UNKNOWN | High Grade B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Diffuse Large B Cell Lymphoma; B-cell Non Hodgkin Lymphoma; Mantle Cell Lymphoma |
Shandong Provincial Hospital |
2021-03-01 | PHASE3 |
| NCT05665530 | Recruiting | Aggressive B-Cell Non-Hodgkin''s Lymphoma|Aggressive B-Cell NHL|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma (MCL)|Richter''s Syndrome|T-cell Lymphoma |
Prelude Therapeutics|BeiGene |
2023-09-12 | Phase 1 |
| NCT05320575 | COMPLETED | HLH |
Beijing Friendship Hospital |
2022-02-01 | PHASE3 |
| NCT05504603 | UNKNOWN | Untreated Mantle Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2020-07-27 | PHASE2 |
| NCT04172246 | COMPLETED | Mature B-cell Malignancies |
BeiGene |
2020-01-29 | PHASE1; PHASE2 |
| NCT05767398 | COMPLETED | Healthy Volunteers |
BeiGene |
2023-03-07 | PHASE1 |
| NCT04899570 | UNKNOWN | Intravascular Large B-Cell Lymphoma |
Peking Union Medical College Hospital |
2021-04-01 | PHASE2 |
| NCT02914938 | TERMINATED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma (FL); Marginal Zone B Cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); High Grade Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma (MCL) |
MEI Pharma, Inc. |
2016-10 | PHASE1 |
| NCT04736914 | UNKNOWN | Mantle Cell Lymphoma |
Sun Yat-sen University |
2021-01-31 | PHASE2 |
| NCT04705129 | UNKNOWN | Primary Mediastinal Large B Cell Lymphoma; EBV-Positive DLBCL, Nos |
Ruijin Hospital |
2021-01-01 | PHASE2 |
| NCT05117814 | UNKNOWN | CNS Lymphoma |
Peking University People's Hospital |
2021-09 | |
| NCT05547399 | COMPLETED | Healthy Volunteers |
BeiGene |
2022-06-07 | PHASE1 |
| NCT04463953 | COMPLETED | Waldenström Macroglobulinemia |
Institute of Hematology & Blood Diseases Hospital, China |
2020-06-01 | PHASE2 |
| NCT04938297 | UNKNOWN | Central Nervous System Lymphoma |
Henan Cancer Hospital |
2021-05-26 | PHASE2 |
| NCT05279872 | COMPLETED | Immune Thrombocytopenia; Bruton Tyrosine Kinase |
Peking University People's Hospital |
2022-01-01 | PHASE2 |
| NCT03734016 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
BeiGene |
2018-11-01 | PHASE3 |
| NCT04899453 | UNKNOWN | Primary Vitreoretinal Lymphoma |
Peking Union Medical College Hospital |
2020-08-01 | PHASE2 |
| NCT03846427 | COMPLETED | Marginal Zone Lymphoma; MZL |
BeiGene |
2019-02-19 | PHASE2 |
| NCT04551963 | COMPLETED | B-cell Malignancies |
BeiGene |
2020-11-15 | PHASE1 |
| NCT04460248 | ACTIVE_NOT_RECRUITING | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2020-08-26 | PHASE2 |
| NCT03332017 | COMPLETED | Relapsed/Refractory Follicular Non-Hodgkin Lymphoma |
BeiGene |
2017-11-14 | PHASE2 |
| NCT03336333 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
BeiGene |
2017-10-31 | PHASE3 |
| NCT02343120 | COMPLETED | B-cell Malignancies |
BeiGene |
2014-09-04 | PHASE1; PHASE2 |
| NCT04382586 | COMPLETED | COVID-19 Pulmonary Complications; COVID-19 |
BeiGene |
2020-07-06 | PHASE2 |
| NCT02795182 | COMPLETED | Lymphoma; Leukemia |
BeiGene |
2016-06-29 | PHASE1 |
| NCT04470908 | COMPLETED | Healthy; Male |
BeiGene |
2020-07-29 | PHASE1 |
| NCT02569476 | COMPLETED | B-cell Lymphoid Malignancies |
BeiGene |
2016-01-13 | PHASE1 |
| NCT03520920 | COMPLETED | Marginal Zone Lymphoma; Follicular Lymphoma; Diffuse Large B-Cell Lymphoma |
BeiGene |
2018-01-04 | PHASE2 |
| NCT03189524 | COMPLETED | B-cell Lymphoma |
BeiGene |
2016-07-05 | PHASE1 |
| NCT03145064 | COMPLETED | Diffuse Large B-cell Lymphoma |
BeiGene |
2017-06-30 | PHASE2 |
| NCT03332173 | COMPLETED | Waldenström's Macroglobulinemia (WM) |
BeiGene |
2017-08-31 | PHASE2 |
| NCT03206970 | COMPLETED | Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma |
BeiGene |
2017-03-02 | PHASE2 |
| NCT03465059 | COMPLETED | Hepatic Insufficiency & Healthy Subjects |
BeiGene |
2018-05-30 | PHASE1 |
| NCT03206918 | COMPLETED | Relapsed or Refractory Chronic Lymphocytic Leukemia; Relapsed or Refractory Small Lymphocytic Lymphoma |
BeiGene |
2017-03-09 | PHASE2 |
| NCT03561298 | COMPLETED | Healthy Subjects |
BeiGene |
2018-06-07 | PHASE1 |
| NCT03432884 | COMPLETED | Healthy Volunteers |
BeiGene |
2018-01-25 | PHASE1 |
| NCT04163523 | COMPLETED | Healthy Volunteers |
BeiGene |
2016-05-25 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-09-02)
Check the
Zanubrutinib (BGB-3111)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Zanubrutinib (BGB-3111) Solubility in DMSO
- Zanubrutinib (BGB-3111) Stock Solution
- Zanubrutinib (BGB-3111) Storage
- Zanubrutinib (BGB-3111) Stability
- Zanubrutinib (BGB-3111) Molecular Weight
- Zanubrutinib (BGB-3111) SMILES
- Zanubrutinib (BGB-3111) CAS Number
- Zanubrutinib (BGB-3111) Chemical Structure (2D and 3D)
- Zanubrutinib (BGB-3111) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.